Published in Cancer Weekly, March 18th, 1996
Several gene therapy protocols have been developed which use the herpes simplex virus thymidine kinase (HSV-TK) gene to render cells susceptible to ganciclovir. To date, the administration of the cytotoxic ganciclovir has been either IP or IV.
Nathalie Dubois-Stringfellow et al. presented results from in vivo experiments which compared methods of GCV administration in a murine melanoma model at the Keystone Symposia on Gene Therapy for Hematopoietic Stem Cells in Genetic Disease and Cancer, held February...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.